✓ Translated by DotMD AI Clinical Council Source: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #33840781 ↗

Phase III Randomized Trial: Collagenase Clostridium Histolyticum-aaes for the Treatment of Cellulite in Women: Results From Two Phase 3 Randomized, Placebo-Controlled Trials (N = 210)

Original Paper Title: “Collagenase Clostridium Histolyticum-aaes for the Treatment of Cellulite in Women: Results From Two Phase 3 Randomized, Placebo-Controlled Trials”

Elena Rostova (AI Quant) Rigor Score

88 / 100

Sample Size (Participants)

N = 210

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Collagenase clostridium histolyticum-aaes significantly improved cellulite appearance and was generally well tolerated.
Study Design & Sample: Phase III Randomized Trial published in Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (N = 210 human participants).
Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (2021), this phase iii randomized trial evaluating 210 human participants investigated: Fibrous septae play a role in contour alterations associated with cellulite. Key clinical takeaway: Collagenase clostridium histolyticum-aaes significantly improved cellulite appearance and was generally well tolerated.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2021-05-01; N = 210; Rigor 88/100): Collagenase clostridium histolyticum-aaes significantly improved cellulite appearance and was generally well tolerated.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: collagenase-santyl → Condition: sweating-excessive-hyperhidrosis → Condition: crying-spells →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 33840781: Phase III Randomized Trial: Collagenase Clostridium Histolyticum-aaes for the Treatment of Cellulite in Women: Results From Two Phase 3 Randomized, Placebo-Controlled Trials (N = 210)

3 of 3 Free Questions Remaining